Product Code: RP-ID-10351966 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10351966
Market Overview:
Global Liquid Biopsy Market Analysis & Outlook 2030
The worldwide liquid biopsy market is estimated to stood at USD 6 billion by 2030, as per report by Kenneth Research., showing a CAGR of 14% during 2022-2030. Improved perspective on tumor given by fluid biopsy innovation is assessed to increase the market in coming years.
While tissue biopsies have been standard for malignant growth finding for recent year, their exceptionally obtrusive nature and every now and again related complexities have been significant concerns. Besides, these biopsies lead to high use being brought about by patients. Fluid biopsies, then again, offer a less obtrusive approach alongside high adequacy. Subsequently, there are various key private associations engaged with thorough R&D exercises for fluid biopsy test improvement and it is inevitable before these methods fill in conspicuousness in analytic gear of oncologists and pathologists.
Further key discoveries from the report recommend:
Mechanical advancements, for example, electric field prompted delivery and estimation (EFIRM)- Liquid Biopsy (eLB), which gives location that can help clinical therapy choices for most normal subtype of diseases are relied upon to drive the take-up of salivation based examining over the gauge time frame. Presently, clinical utilization of disengagement and identification innovation is restricted to CTC quantitation however the quantity of CTCs is found to hold huge connection with infection seriousness. This is, hence, assessed to increase the market throughout the next few years
Rising mindfulness in regards to benefits of numerous quality investigation alongside the assistance of NGS is expected to help the development of the market. Associations like American Society of Clinical Oncology (ASCO) are occupied with supporting execution of fluid biopsy, which thusly is probably going to spike the development of the market
Escalating contest between biotech organizations and expanding speculations by government in medical care establishments will prompt improvement of more refined tests. Organizations occupied with R&D and commercialization of these items incorporate Pathway Genomics; Natera Inc.; Epic Sciences; Illumina; Foundation Medicine; Roche; LabCorp; and Sequenom
The market has fragmented the worldwide fluid biopsy marketon the premise of utilization, test type, biomarker, innovation, and district:
Fluid Biopsy Application Outlook (Revenue, USD Million, 2022-2030)
Treatment Selection for Metastatic Breast Cancer (MBS)
Treatment Selection for Other Metastatic Cancer
Sub-atomic Health Monitoring
Fluid Biopsy Sample Type Outlook (Revenue, USD Million, 2022-2030)
Blood Sample based
Pee Sample based
Other Bio Fluids (Tissue liquids and Saliva) based
Fluid Biopsy Biomarker Outlook (Revenue, USD Million, 2022-2030)
Circling Tumor Cells (CTC)
Circling Tumor DNA (ctDNA)
Exosomes
Fluid Biopsy Technology Outlook (Revenue, USD Million, 2022-2030
Multi-quality equal Analysis (NGS)
Single Gene Analysis (PCR Microarrays)
Related Reports
Proof of Quality & Reliability
